市場調査レポート
商品コード
1178755
生検針の世界市場:市場規模(製品別、用途別、最終用途別)、地域別の展望、産業分析、成長性、競合市場シェア、予測(2023年~2032年)Biopsy Needle Market Size By Product, By Application, By End-use, Regional Outlook, Industry Analysis Report, Growth Potential, Competitive Market Share & Forecast, 2023 - 2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
生検針の世界市場:市場規模(製品別、用途別、最終用途別)、地域別の展望、産業分析、成長性、競合市場シェア、予測(2023年~2032年) |
出版日: 2022年12月20日
発行: Global Market Insights Inc.
ページ情報: 英文 275 Pages
納期: 2~3営業日
|
世界の生検針市場は、新しい生検針を開発するための絶え間ない技術的進歩により、2023年~2032年の間に大きな成長を示すと予想されています。
また、組織スキャンや小さながん腫瘍の検出のための革新的な技術の利用可能性は、予測期間中に業界の成長を後押しします。さらに、高所得国の政府や公的医療保険会社が提供するいくつかの償還政策やインセンティブは、生検針市場の拡大をさらに推進する予定です。
当レポートでは、世界の生検針市場について調査分析し、業界の考察、セグメント分析、地域分析、企業プロファイルなどを提供しています
Biopsy Needle Market is slated to demonstrate massive growth between 2023 and 2032, owing to the constant technological advancements for developing novel biopsy needles. In addition, the availability of innovative technologies for tissue scanning and detecting small cancerous tumors will bolster the industry growth over the forecast period.
Besides, several reimbursement policies and incentives offered by governments or public health insurance firms in high-income countries are further slated to propel the biopsy needles market expansion.
The competitive landscape of the biopsy needle market is highly intact. Key players in the market are constantly engaging in strategic initiatives, including partnerships, mergers and acquisitions, and product launches, to strengthen their market positions. For instance, in December 2022, Olympus Corporation announced inking a definitive agreement to acquire Odin Vision, a cloud-based AI endoscopy company, in a deal worth USD 79 million in upfront and milestone-based payments.
In yet another example, Boston Scientific received FDA approval for the extended labeling of the WATCHMAN FLX™ LAAC Device, which can be used for dual anti-platelet therapy as a medication after the procedure.
Overall, the biopsy needle market is classified in terms of product, application, end-user, and region.
On the basis of product, the market share from biopsy needles segment is slated to grow exponentially over the foreseeable period. The multiple benefits offered by biopsy needles including high cost affordability and robust operational speed would boost the product demand in the ensuing years.
Considering the application, the cancer/tumor segment held approximately 50% of the market share in 2022 and is expected to grow considerably through 2032. Needle biopsy reveals whether a lump or mass is an infection, a cyst, a benign tumor, or cancer, which is expected to propel segment growth substantially. In addition, the introduction of several new cancer diagnosis centers and products by leading market players is estimated to propel the segmental growth in the future.
Based on the end-user, the hospital segment is expected to register massive growth through 2032. Needle biopsies are performed using CT scan, MRI, mammogram, or ultrasound, which can be done easily in hospitals, further supporting the segmental expansion in the coming years.
Regionally, the North America biopsy needle market held over 48% market share in 2022 and is slated to demonstrate massive growth through 2032. This can be attributed to the constant product development in the healthcare sector, rising awareness regarding infectious diseases, and increasing application of point-of-care diagnostic devices for safe and early disease detection. In addition, the presence of several established key players and highly developed co-payment and insurance systems will positively impact the overall market outlook in the region.